Literature DB >> 27304088

Enantioselective synthesis of chiral α,β-unsaturated γ-substituted butyrolactams by organocatalyzed direct asymmetric vinylogous Michael addition of α,β-unsaturated γ-butyrolactam to 2-enoylpyridines.

Zhen-Hua Wang1, Zhi-Jun Wu2, Deng-Feng Yue1, Yong You1, Xiao-Ying Xu3, Xiao-Mei Zhang3, Wei-Cheng Yuan3.   

Abstract

An organocatalyzed direct asymmetric vinylogous Michael addition reaction of α,β-unsaturated γ-butyrolactam to 2-enoylpyridines has been developed with a chiral bifunctional amine-squaramide as the catalyst. This approach provides easy access to a series of optically active α,β-unsaturated γ-substituted butyrolactams in high yields (up to 99%) with excellent diastereoselectivities (up to >99 : 1) and enantioselectivities (up to >99% ee).

Entities:  

Year:  2016        PMID: 27304088     DOI: 10.1039/c6ob01191h

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  4 in total

1.  Phosphine-mediated enantioselective [1 + 4]-annulation of Morita-Baylis-Hillman carbonates with 2-enoylpyridines.

Authors:  Tao Wang; Pengfei Zhang; Wenjun Li; Pengfei Li
Journal:  RSC Adv       Date:  2018-12-12       Impact factor: 3.361

Review 2.  Unique indolizidine alkaloid securinine is a promising scaffold for the development of neuroprotective and antitumor drugs.

Authors:  Sergey Klochkov; Margarita Neganova
Journal:  RSC Adv       Date:  2021-05-26       Impact factor: 4.036

3.  Asymmetric and Site-Selective [3 + 2]-Annulations for the Synthesis of High-Value Bicyclic Lactams.

Authors:  Dimitris Kalaitzakis; Manolis Sofiadis; Myron Triantafyllakis; Konstantinos Daskalakis; Georgios Vassilikogiannakis
Journal:  Org Lett       Date:  2018-02-08       Impact factor: 6.005

4.  Novel bivalent securinine mimetics as topoisomerase I inhibitors.

Authors:  Wen Hou; Hui Lin; Zhen-Ya Wang; Martin G Banwell; Ting Zeng; Ping-Hua Sun; Jing Lin; Wei-Min Chen
Journal:  Medchemcomm       Date:  2017-01-03       Impact factor: 3.597

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.